Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Jacobs

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
Drugs|March 5, 2017
The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsPaul Declerck, Romano Danesi, Danielle Petersel, et al.
Clinical Breast Cancer|March 12, 2018
The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast CancerKimberly Blackwell, Joseph Gligorov, Ira Jacobs, et al.
European Journal of Applied Physiology|March 31, 2026
The effects of ischemic preconditioning and placebo maneuvers are similar during arm-cranking performance in upper-body trained athletesLiam O'Brien, Mackenzie McLaughlin, Jenna Gillen, et al.
Human Psychopharmacology|July 15, 2004
Effects of modafinil on cognitive and meta-cognitive performanceJoseph V Baranski, Ross Pigeau, Peter Dinich, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 24, 2018
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular LymphomaLorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, et al.
Biologics : Targets & Therapy|March 11, 2017
A practical guide about biosimilar data for health care providers treating inflammatory diseasesJoseph Markenson, Daniel F Alvarez, Ira Jacobs, et al.
Dermatology and Therapy|March 18, 2018
Biosimilar Drugs for Psoriasis: Principles, Present, and Near FutureJose-Manuel Carrascosa, Ira Jacobs, Danielle Petersel, et al.
Critical Reviews in Oncology/Hematology|June 30, 2016
Biosimilars: Extrapolation for oncologyGiuseppe Curigliano, Darran P O'Connor, Julie A Rosenberg, et al.
Pharmaceuticals (Basel, Switzerland)|January 31, 2017
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician SurveyBradley J Monk, Philip E Lammers, Thomas Cartwright, et al.
Cancer Management and Research|June 16, 2017
Can biosimilars help achieve the goals of US health care reform?Ralph Boccia, Ira Jacobs, Robert Popovian, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
Drugs|March 5, 2017
The Language of Biosimilars: Clarification, Definitions, and Regulatory AspectsPaul Declerck, Romano Danesi, Danielle Petersel, et al.
Clinical Breast Cancer|March 12, 2018
The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast CancerKimberly Blackwell, Joseph Gligorov, Ira Jacobs, et al.
European Journal of Applied Physiology|March 31, 2026
The effects of ischemic preconditioning and placebo maneuvers are similar during arm-cranking performance in upper-body trained athletesLiam O'Brien, Mackenzie McLaughlin, Jenna Gillen, et al.
Human Psychopharmacology|July 15, 2004
Effects of modafinil on cognitive and meta-cognitive performanceJoseph V Baranski, Ross Pigeau, Peter Dinich, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 24, 2018
An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular LymphomaLorenzo Falchi, Alessandra Ferrajoli, Ira Jacobs, et al.
Biologics : Targets & Therapy|March 11, 2017
A practical guide about biosimilar data for health care providers treating inflammatory diseasesJoseph Markenson, Daniel F Alvarez, Ira Jacobs, et al.
Dermatology and Therapy|March 18, 2018
Biosimilar Drugs for Psoriasis: Principles, Present, and Near FutureJose-Manuel Carrascosa, Ira Jacobs, Danielle Petersel, et al.
Critical Reviews in Oncology/Hematology|June 30, 2016
Biosimilars: Extrapolation for oncologyGiuseppe Curigliano, Darran P O'Connor, Julie A Rosenberg, et al.
Pharmaceuticals (Basel, Switzerland)|January 31, 2017
Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician SurveyBradley J Monk, Philip E Lammers, Thomas Cartwright, et al.
Cancer Management and Research|June 16, 2017
Can biosimilars help achieve the goals of US health care reform?Ralph Boccia, Ira Jacobs, Robert Popovian, et al.
Pageof 9